Beneficial effect of *Flos magnoliae* extract on multiple low dose streptozotocin-induced type 1 diabetes development and cytokine-induced β-cell damage

EUN-KYUNG KIM1*, MI-YOUNG SONG1*, IN-SEOB KIM2, WOO SUNG MOON3, DO-GON RYU2, HONG-SEOB SO4, RAEKIL PARK4, JIN-WOO PARK1, KANG-BEOM KWON2,4 and BYUNG-HYUN PARK1

Departments of 1Biochemistry, and 3Pathology, Medical School and Institute for Medical Sciences, Chonbuk National University, Jeonju, Jeonbuk 561-756; 2Department of Physiology, School of Oriental Medicine, and 4Vestibulocochlear System Research Center and Department of Microbiology, College of Medicine, Wonkwang University, Iksan, Jeonbuk 570-749, Korea

Received June 9, 2008; Accepted July 28, 2008

DOI: 10.3892/ijmm_00000046

**Abstract.** In the present study, *Flos magnoliae* extract (FME) was evaluated to determine if it could protect pancreatic β-cells against multiple low dose streptozotocin (MLDS) and interleukin-1β and interferon-γ. Injection of mice with MLDS resulted in hyperglycemia and hypoinsulinemia, which was confirmed by immunohistochemical staining. However, the induction of diabetes by MLDS was completely prevented when mice were pretreated with FME. FME also effectively protected β-cells against cytokine toxicity, which was demonstrated by an increase in the viability of rat insulinoma RINm5F cells and by preserved insulin secreting responses to glucose in isolated rat islets. Moreover, cytokine-induced nitric oxide production and iNOS mRNA and protein expression were significantly reduced in RINm5F cells and islets that were preincubated with FME. The molecular mechanism by which FME inhibits iNOS gene expression in *in vitro* and *in vivo* appears to involve inhibition of NF-κB activation. Taken together, these results reveal the possible therapeutic value of FME for the prevention of type 1 diabetes progression.

**Introduction**

Insulin-dependent diabetes mellitus (IDDM) is an autoimmune disease that results from the selective destruction of pancreatic β-cells (1). During early stages of the disease, histological findings reveal features of insulitis, which is characterized by the infiltration of immune cells such as T lymphocytes, macrophages, and natural killer cells into pancreatic islets (2,3). These infiltrated cells then produce and release various cytokines, which act as humoral mediators of the immunologic process. Therefore, cytokines such as interleukin-1β (IL-1β), tumor necrosis factor-α, and interferon-γ (IFN-γ) have been implicated as key effector molecules in β-cell function and viability (4). IL-1β alone or in combination with tumor necrosis factor-α or IFN-γ upregulates inducible nitric oxide synthase (iNOS) and produces high levels of nitric oxide (NO) in pancreatic islets (5,6). NO is produced by the oxidation of L-arginine to L-citruline by nitric oxide synthase (NOS), and excess NO is known to inhibit mitochondrial metabolism, to modify protein, and to cleave DNA (7,8).

Alloxan and streptozotocin (STZ) are two agents commonly used to induce diabetes. These structurally diverse compounds have a long history of use in diabetes research and are known to be specifically toxic to pancreatic β-cells (9). Alloxan is thought to produce oxygen-free radicals (10), whereas STZ contains a nitroso moiety and releases NO during its metabolism (11-13). STZ induces β-cell damage by two different mechanisms according to the concentrations used (14). A single high dose of STZ rapidly destroys β-cells via direct cytotoxic action that occurs primarily as a result of alklylation and cleavage of the DNA (15). Multiple low doses of STZ (MLDS) activates immune mechanisms and induces inflammation of the islets. There is evidence that NO mediates the deleterious effects of MLDS on β-cell dysfunction and destruction (16,17), and Flodström *et al* (18) reported that iNOS knock-out mice are resistant to the induction of diabetes by MLDS.
The transcriptional nuclear factor κB (NF-κB), which can be activated by cytokine and STZ, is a key signaling mediator of iNOS induction (19-21). The importance of NF-κB in MLDS is underscored by the fact that mice that do not possess the p50 subunit of NF-κB are not susceptible to MLDS-induced diabetes (22). In addition, we previously demonstrated that NF-κB-dependent iNOS expression played a key role in the dysfunction and destruction of β-cells (21).

The flower buds of Magnolia denudata Desrousseaux, which are known as Flos magnoliae, are commonly used in traditional Chinese medicine to treat nasal congestion with headache, sinusitis and allergic rhinitis. Moreover, it has been reported that Flos magnoliae extract (FME) has an anti-angiogenic (23) and an anti-inflammatory effect (24). In this study, we demonstrated that FME inhibited the development of diabetes, indicating that FME has the potential for use as a therapeutic agent to treat diabetes.

Materials and methods

Cell culture. RINm5F (RIN) cells were purchased from the American Type Culture Collection and grown at 37˚C under a humidified, 5% CO2 atmosphere in RPMI-1640 medium supplemented with 10% fetal bovine serum and 2 mM glutamine, 100 units/ml of penicillin, 100 μg/ml of streptomycin and 2.5 μg/ml of amphotericin B.

Preparation of Flos magnoliae extract. The plant was purchased from Wonkwang Oriental Medical Hospital in Iksan, Jeonbuk, Korea and identified as Flos magnoliae by Ho-Joon Song, keeper of the Herbarium. Voucher samples were preserved for reference in the Herbarium of the Department of Physiology, School of Oriental Medicine, Wonkwang University (Omehy, 2005-82). For extraction, 200 g of Flos magnoliae was ground and extracted in boiling water for 4 h. The sample was then centrifuged at 3,000 x g for 20 min, after which the supernatant was concentrated to 200 ml under reduced pressure and then freeze dried to 16.8 g.

Animals. Specific pathogen-free female ICR mice were purchased from Orientbio Inc. (Seoungnam, Korea) and housed at our animal facility for one week prior to use. All mice used were 5-6 weeks old, and were kept under specific pathogen-free conditions with free access to a standard commercial diet. To induce diabetes, the mice received an i.p. injection of freshly prepared STZ (50 mg/kg body weight; 0.2 ml) dissolved in sodium citrate buffer (pH 4.0) once a day, for 5 consecutive days. In addition, some mice were administered 250 mg/kg FME daily by oral gavage for 3 days prior to being administered the STZ injections. The mice were divided into the following groups: i) the non-treated control group, ii) the MLDS group, and iii) the FME + MLDS group (n=5, each group). The day on which the first STZ injection was administered is defined as day 1. Control group animals were administered citrate buffer alone. At day 5, the mice were sacrificed by decapitation without anesthesia, and the trunk blood was collected in prechilled tubes that contained 1 mg/ml of EDTA. The plasma glucose was then assayed by the glucose oxidase method (Sigma, St. Louis, MO), and the plasma insulin was measured using an ELISA kit (Linco Research, St. Charles, MO). All experimental procedures were approved by the Institutional Animal Care and Use Committee at Chonbuk National University.

Immunohistochemistry. The Dako Envision system (Dako, Carpinteria, CA), which used dextran polymers conjugated with horseradish peroxidase, was employed for immunohistochemical staining to avoid any endogenous biotin contamination. The pancreases were removed from the sacrificed mice, and then immediately fixed in 0.1 M PBS that contained 10% formalin. The fixed samples were then embedded in paraffin tissue blocks, after which 4-μm histologic sections were cut. Next, the samples were deparaffinized, after which the tissue sections were placed in 10 mM sodium citrate and treated using the microwave antigen retrieval procedure. The endogenous peroxidase was then blocked, after which the sections were then incubated with Protein Block Serum-Free (Dako) to block nonspecific staining. The sections were then incubated with anti-insulin antibody (Santa Cruz Biochemicals, Santa Cruz, CA), after which the peroxidase activity was detected using the enzyme substrate 3-amino-9-ethyl carbazole.

MTT assay for cell viability. The viability of cultured cells was determined by assaying the reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) to formazan. Briefly, the cells were treated with cytokine for 24 or 48 h, after which they were washed twice with PBS. Next, MTT (100 μg/100 μl of PBS) was added, and the cells were then incubated at 37˚C for 1 h, after which DMSO (100 μl) was added to dissolve the formazan crystals. The absorbance was then measured at 570 nm using a spectrophotometer.

5-Bromo-2-deoxyuridine (BrdU)-labeling cell proliferation assay. A cell proliferation enzyme-linked immunosorbant assay (BrdU kit; Amersham Biosciences, Piscataway, NJ) was used to measure the incorporation of BrdU during DNA synthesis following the manufacturer's protocols. Briefly, following treatment with cytokine for 24 or 48 h, BrdU (10 μM) was added to the culture medium for 2 h. Next, the BrdU-labeled cells were fixed, and the DNA was then denatured in fixative solution for 30 min at room temperature. The cells were then incubated with peroxidase-conjugated anti-BrdU antibody for 2 h at room temperature, followed by washing three times with washing solution. The immune complex was then detected by inducing a 3,3′,5,5′-tetramethylbenzidine substrate reaction and then measuring the absorbance at 405 nm.

NO measurement. Biologically produced NO is rapidly oxidized to nitrite and nitrate in aqueous solutions (25). Therefore, NO production was evaluated by measuring the nitrite concentrations in the cell-free culture supernatant using a colorimetric assay. Briefly, following treatment with cytokine for 24 h, 100-μl aliquots of the culture supernatants were incubated with 100 μl of a modified Griess reagent (1:1 mixture of 1% sulfanilamide in 30% acetic acid and 0.1% N-(1-naphthyl)ethylenediamine dihydrochloride in 60% acetic acid) at room temperature for 5 min, at which time the
Western blot analysis. Cells or islets were homogenized in 100 μl of ice-cold lysis buffer (20 mM HEPES, pH 7.2, 1% Triton X-100, 10% glycerol, 1 mM PMSF, 10 μg/ml leupeptin and 10 μg/ml aprotinin). The homogenates, which contained 20 μg of protein, were then separated by SDS-PAGE with 7.5% (for iNOS) or 12% resolving (for IκB, p65, β-actin and PCNA) and 3% acrylamide stacking gels, after which they were transferred to nitrocellulose sheets. Next, the nitrocellulose paper was blocked with 2% bovine serum albumin (Santa Cruz Biochemicals). Horseradish peroxidase-conjugated IgG (Zymed, South San Francisco, CA) was used as a secondary antibody. The protein expression levels were then determined by analyzing the signals captured on the nitrocellulose membranes using an ABI PRISM 7900HT Sequence Detection System (Applied Biosystems). All reactions were conducted in triplicate.

RNA isolation and real-time PCR for iNOS. Total RNA was isolated from RIN cells or islets using Trizol reagent (Invitrogen, Carlsbad, CA). The RNA was then precipitated with isopropanol and dissolved in DEPC-treated distilled water. The total RNA (2 μg) was then treated with RNase-free DNase (Invitrogen), after which first-strand cDNA was generated using the random hexamer primer provided in the first-strand cDNA synthesis kit (Applied Biosystems, Foster City, CA). The following specific primers for iNOS were designed using the primer express software (Applied Biosystems): iNOS (accession no. NM_012611), 5'-TGTGCGGAAAGGTCTAT-3' (forward), and 5'-GCAGTTT CCTGTCTCAGTACGAA-3' (reverse). The sequence for the control 18S ribosomal RNA was purchased from Applied Biosystems and used as the invariant control. A reaction mixture with a final volume of 10 μl that contained 10 ng of reverse transcribed total RNA, 167 nM of forward and reverse primers and 2X PCR Master mix was then subjected to real-time PCR, which was conducted in 384-well plates using an ABI PRISM 7900HT Sequence Detection System (Applied Biosystems). All reactions were conducted in triplicate.

Preparation of nuclear extracts. After treatment with cytokine or STZ, cells or pancreatic tissues were homogenized and washed twice with ice-cold PBS (pH 7.9) and then pelleted by centrifugation at 12,000 x g for 30 sec. Next, the pellet was suspended in cold hypotonic lysis buffer (10 mM HEPES, 1.5 mM MgCl2, 0.2 mM KCl, 0.2 mM PMSF and 0.5 mM dithiothreitol), vortexed for 10 sec, and then incubated on ice for 15 min. The packed cells were then re-suspended in ice-cold hypotonic lysis buffer in the presence of 50 μl of 10% Nonidet P-40, after which they were incubated on ice for 25 min. Next, the nuclear fraction was precipitated by centrifugation at 13,000 x g for 1 min at 4°C, after which the supernatants (cytosol extracts) were collected and stored at -80°C. The pelleted nuclei were then re-suspended in 50-100 μl of low salt extraction buffer (20 mM HEPES, pH 7.9, 1.5 mM MgCl2, 25% glycerol, 20 mM KCl, 0.2 mM EDTA, 0.2 mM PMSF and 0.5 mM dithiothreitol), added to an equal volume of high salt extraction buffer (20 mM HEPES, pH 7.9, 1.5 mM MgCl2, 25% glycerol, 80 mM KCl, 0.2 mM EDTA, 0.2 mM PMSF and 0.5 mM dithiothreitol) in a dropwise fashion, and then incubated under continuous shaking at 4°C for 45 min. The sample was then centrifuged for 20 min at 12,000 x g. Next, the protein concentrations of the samples were determined, after which aliquots of the nuclear extracts were stored at -80°C until needed.

Electrophoretic mobility shift assay (EMSA). The activation of NF-kB was assayed by a gel mobility shift assay using nuclear extracts from control and treated cells. Briefly, an oligonucleotide containing the κB binding site (κB, 5'-CCGTTAACAGAGGGCGTTCCCGAG-3') was synthesized and used as a probe for a gel retardation assay. The two complementary strands were then annealed and labeled with [α-32P]dCTP. The labeled oligonucleotides (10,000 cpm), 10 μg of nuclear extracts and binding buffer (10 mM Tris-HCl, pH 7.6, 500 mM KCl, 10 mM EDTA, 50% glycerol, 100 ng poly(dI·dC), 1 mM dithiothreitol) were then incubated for 30 min at room temperature in a final volume of 20 μl. Next, the reaction mixtures were analyzed by electrophoresis on 4% polyacrylamide gels in 0.5X Tris-borate buffer, after which the gels were dried and examined by autoradiography.

Isolation of islets and insulin secretion assay. Pancreatic islets were isolated from male Sprague-Dawley rats using the collagenase digestion method, as described previously (26). Briefly, the cells were treated with cytokine for 24 h, after which the islets were washed three times in Krebs-Ringer bicarbonate buffer (25 mM HEPES, 115 mM NaCl, 24 mM NaHCO3, 5 mM KCl, 1 mM MgCl2, 2.5 mM CaCl2, and 0.1% bovine serum albumin, pH 7.4) containing 3 mM D-glucose. The insulin secretion was then measured by static incubation of the islets for 30 min in the presence of either 5.5 or 20 mM D-glucose. The insulin content of the medium was then determined by ELISA.

Statistical analysis. Statistical analysis of the data was performed using ANOVA and Duncan’s test. Differences with a p<0.05 were considered statistically significant.

Results

FME has an anti-diabetic effect in mice. Mice that were injected with MLDS gradually became hyperglycemic (i.e. fasting blood glucose concentrations ≥126 mg%), with an increased incidence of diabetes being observed from day 3 onwards. The blood glucose level of the mice that were injected with MLDS at day 3 was 214.3±20.3 mg%; however, the mice that were pretreated with FME were fully resistant to the development of diabetes (Fig. 1A). In addition, treatment with FME alone did not affect the blood glucose concentration in mice (data not shown). Furthermore, the plasma insulin level at day 5 in the MLDS group decreased by 82.4% (from 6.32±0.41 to 1.11±0.12 ng/ml), whereas the severity of hypoinsulinemia was attenuated in mice that were pretreated with FME (Fig. 1B). These results indicate that FME is protective against MLDS-induced diabetes.
The preventive effect of FME on MLDS-induced diabetes was histologically examined. Pancreatic tissues were obtained 5 days after MLDS administration with or without FME pretreatment and then subjected to H&E staining and immunohistochemistry. H&E staining revealed that diabetic mice had degenerative and necrotic changes and islet shrinkage (Fig. 1C, b), as well as weak insulin-reactivity in a few β-cells (Fig. 1C, e). However, H&E staining and immunohistochemistry of samples collected from diabetic mice that were pretreated with FME revealed the presence of round, nearly normal and clearly defined islets that were strongly positive for insulin (Fig. 1C, c and f).

To elucidate the anti-diabetogenic mechanism of FME, we examined its effect on MLDS-induced NF-κB activation. The findings of this investigation were similar to those of a previous study, which demonstrated that STZ treatment resulted in NF-κB activation in mice (27). Fig. 1D is a representative EMSA radiograph showing the 32P-DNA/NF-κB complex in nuclear extracts of the pancreas 5 days after MLDS administration. In contrast, this complex was not detected in nuclear extracts obtained from the pancreases of FME-pretreated mice. Taken together, these results show that FME inhibits the translocation of NF-κB to the nucleus in mice.

FME prevents cytokine-mediated cell death by RIN cells. We next investigated the anti-diabetogenic effect of FME at the cellular level. Based on a previous study (28), a cytokine mix consisting of IL-1β (5 ng/ml) and IFN-γ (100 U/ml) was employed throughout the current study to maintain the stable toxic effectiveness of the cytokine exposure protocol. RIN cells from a rat pancreatic β-cell line were cultured to near confluence and then cells that had been pretreated with or without FME for 3 h were exposed to cytokine for 24 or 48 h, after which their viability was assessed using MTT assay. Treatment with cytokine significantly reduced the cell viability to 45.6±1.1% at 24 h and 22.0±0.4% at 48 h when compared to that of the control (Fig. 2A). Conversely, FME increased the viability of cytokine-treated RIN cells in a concentration-dependent manner. The beneficial effect of FME on cytokine-mediated viability reduction was further confirmed by evaluating the BrdU incorporation in RIN cells. Treatment with cytokine for 24 or 48 h reduced the level of BrdU incorporation, and therefore proliferation, to 56.9±6.1 and 36.7±4.0% of the control levels, respectively. Similar to the MTT assay data, FME prevented the cytokine-mediated

Figure 1. FME protects islets from MLDS-induced destruction. ICR mice were injected with FME via oral administration of a daily dose of 250 mg/kg for 3 days, and then injected with STZ (50 mg/kg) via i.p. daily for 5 days. Levels of fasting glucose (A) and insulin were then determined (B). (C) Pancreases were obtained from normal controls (a, d), STZ-injected (b, e), and FME and STZ-injected mice (c, f). The cellular morphologies of these islets and of the adjoining exocrine regions were then counterstained with H&E (a-c). Islets were labeled for insulin antibody and peroxidase-labeled anti-rabbit IgG and then examined by microscopy (d-f). (D) Nuclear extracts from pancreatic tissues were prepared 5 days after STZ injection and the DNA binding of NF-κB was analyzed by EMSA. **p<0.01 vs. untreated control; ##p<0.01 vs. STZ-injected group.

The preventive effect of FME on MLDS-induced diabetes was histologically examined. Pancreatic tissues were obtained 5 days after MLDS administration with or without FME pretreatment and then subjected to H&E staining and immunohistochemistry. H&E staining revealed that diabetic mice had degenerative and necrotic changes and islet shrinkage (Fig. 1C, b), as well as weak insulin-reactivity in a few β-cells (Fig. 1C, e). However, H&E staining and immunohistochemistry of samples collected from diabetic mice that were pretreated with FME revealed the presence of round, nearly normal and clearly defined islets that were strongly positive for insulin (Fig. 1C, c and f).

To elucidate the anti-diabetogenic mechanism of FME, we examined its effect on MLDS-induced NF-κB activation. The findings of this investigation were similar to those of a previous study, which demonstrated that STZ treatment resulted in NF-κB activation in mice (27). Fig. 1D is a representative EMSA radiograph showing the 32P-DNA/NF-κB complex in nuclear extracts of the pancreas 5 days after MLDS administration. In contrast, this complex was not detected in nuclear extracts obtained from the pancreases of FME-pretreated mice. Taken together, these results show that FME inhibits the translocation of NF-κB to the nucleus in mice.

FME prevents cytokine-mediated cell death by RIN cells. We next investigated the anti-diabetogenic effect of FME at the cellular level. Based on a previous study (28), a cytokine mix consisting of IL-1β (5 ng/ml) and IFN-γ (100 U/ml) was employed throughout the current study to maintain the stable toxic effectiveness of the cytokine exposure protocol. RIN cells from a rat pancreatic β-cell line were cultured to near confluence and then cells that had been pretreated with or without FME for 3 h were exposed to cytokine for 24 or 48 h, after which their viability was assessed using MTT assay. Treatment with cytokine significantly reduced the cell viability to 45.6±1.1% at 24 h and 22.0±0.4% at 48 h when compared to that of the control (Fig. 2A). Conversely, FME increased the viability of cytokine-treated RIN cells in a concentration-dependent manner. The beneficial effect of FME on cytokine-induced viability reduction was further confirmed by evaluating the BrdU incorporation in RIN cells. Treatment with cytokine for 24 or 48 h reduced the level of BrdU incorporation, and therefore proliferation, to 56.9±6.1 and 36.7±4.0% of the control levels, respectively. Similar to the MTT assay data, FME prevented the cytokine-mediated
decrease in cell proliferation potential in a concentration-dependent manner (Fig. 2B). Furthermore, treatment with FME alone did not affect cell viability at the concentrations used in this study (data not shown).

FME inhibits cytokine-mediated iNOS expression by inhibiting NF-κB. NO production under the same conditions was also evaluated. Control RIN cells generated 16.8±0.5 μM of nitrite, whereas cytokine-treated cells generated 62.6±1.3 μM of nitrite in 24 h (Fig. 3). Conversely, a concentration-dependent reduction in cytokine-mediated nitrite production was observed in RIN cells treated with cytokine plus FME. Near complete inhibition of nitrite production was observed in cells that were pretreated with 1.0 mg/ml FME. Furthermore, nitrite production was not observed in cells that were treated with FME alone (data not shown).

To investigate the regulating effect of FME on NO production, we examined the effects of FME on cytokine-induced iNOS mRNA and protein expression using real-time PCR and Western blotting, respectively. As shown in Fig. 3, cytokine increased iNOS mRNA and protein levels. However, when cells were treated with FME prior to cytokine treatment, the iNOS mRNA and protein levels were reduced in a dose-
dependent manner with effects being observed in response to treatment with 0.1 mg/ml of FME, and treatment with 1.0 mg/ml of FME completely blocking the iNOS mRNA and protein expression.

NF-κB has been implicated in the toxicity of MLDS (Fig. 1D), therefore the effect of FME on the cytokine-stimulated translocation of NF-κB from the cytosol to the nucleus in RIN cells was evaluated. Nuclear extracts from cytokine-stimulated RIN cells showed an increase in NF-κB binding activity (Fig. 4A, lane 2) as well as an increased p65 subunit level in their nuclei (Fig. 4B) when compared to unstimulated cells. Conversely, cytokine-induced NF-κB activation was markedly suppressed by pretreatment with FME, which suggests that FME inhibits iNOS expression through the inhibition of NF-κB activation. The specificity of the DNA-NF-κB interaction was demonstrated by competitive assays using a 50-fold excess of unlabeled oligonucleotide (Fig. 4A, lane 6).

We previously reported that IκBα, but not IκBβ, was the major participant in cytokine-induced NF-κB activation (21). Therefore, we investigated the alteration of IκBα levels in the cytosol fraction following cytokine treatment (Fig. 4B). Cytokine-treated RIN cells showed a decreased level of IκBα protein in the cytosol when compared to a similar fraction of the unstimulated cells; however, the increased IκBα degradation that occurred as a result of cytokine treatment was markedly suppressed by pretreatment with FME.

Suppression of the cytokine-induced NF-κB pathway and preservation of glucose-stimulated insulin secretion (GSIS) by FME in rat islets. We further assayed the preventive effects of FME using rat pancreatic islets isolated from male Sprague-Dawley rats. Incubation of rat islets for 24 h with cytokine resulted in a 2.7-fold increase in NO production (Fig. 5A). Additionally, real-time PCR and Western blot analysis revealed that the iNOS mRNA and protein levels were markedly increased by cytokine (Fig. 5A). Similar to the results obtained using the RIN cells, pretreatment of the islets with FME abolished the effects of cytokine and abrogated the levels of NO production and iNOS expression to those of the control islets. Additionally, treatment with cytokine also increased the NF-κB DNA binding activity in islets (Fig. 5B), and pretreatment of the islets with FME completely abolished these effects. To add functional data, FME was evaluated to determine if it could protect against cytokine-induced impairment of GSIS. After 24 h of exposure to the cytokine, insulin secretion was assayed in response to 20 mM glucose. Control islets secreted insulin at a concentration of 20.1±2.3 ng/ml, whereas insulin secretion from cytokine-treated islets decreased significantly to 11.1±0.8 ng/ml (p<0.01) (Fig. 5C). However, pretreatment with FME blocked the effect of the cytokine and restored islet cell insulin secretion to levels.
similar to those of the control. In addition, treatment with FME alone did not affect the insulin secreting response to glucose.

**Discussion**

In this study, we presented a mode of action by which pretreatment with FME resulted in protection against the development of type 1 diabetes in response to MLDS. In addition, β-cell protective effects of FME towards toxic challenge of cytokine in RIN cells and islets were demonstrated.

In the first series of experiments, NF-κB activation in response to injection with MLDS and its prevention by FME was evaluated in mice. An EMSA study revealed that increased NF-κB binding activity occurred in pancreatic nuclear extracts derived from MLDS-injected hyperglycemic diabetic mice. NF-κB participates in the transcriptional regulation of cytokine genes, and their activation results in the production of pro-inflammatory cytokine (29,30); therefore, NF-κB may be a key regulator in the pathway of local cytokine responses involved in MLDS-mediated β-cell destruction. Moreover, it has been reported that T-cell mediated inflammatory reactions are stimulated only in the MLDS model, but not after administration of a single high dose of STZ (9), which suggests that NF-κB plays a key role in MLDS-induced insulitis in pancreatic islets. MLDS-injected mice also showed marked islet destruction and relatively small numbers of insulin-positive β-cells, whereas well-defined islets and strong insulin-positive staining were observed in FME pretreated mice. In addition, pretreatment with FME prevented NF-κB activation, which resulted in the maintenance of plasma glucose and insulin levels during the normal range. Taken together, these results suggest that manipulation of NF-κB activity by FME in pancreatic β-cells allows these cells to withstand and survive MLDS-mediated immune attack.

Similar effects of FME were observed in RIN cells and rat islets exposed to cytokine. The reduction in NO production by FME in RIN cells or islets was associated with a reduction in NF-κB activation and iNOS mRNA expression. In pancreatic β-cells, increased NO production in response to NF-κB activation appears to be an important signal in cytokine-induced apoptosis because inhibition of iNOS has been shown to prevent apoptosis (5,6). Therefore, the process leading to NO production in response to cytokine has been targeted for the treatment of type 1 diabetes. The effects of NO suppression and the associated reduction in cytokine toxicity induced by FME are similar to the results of previously conducted studies that have found that natural products or dietary supplements reduce iNOS expression and protect β-cells from cytokine toxicity (28,31-33). In addition, chemical donors of NO or cytokine promote ER stress (34), activation of MAPK (32), and activation of the JAK-STAT pathways (33) in β-cells. Therefore, we cannot exclude the possibility that the aforementioned pathways are involved in our system and that the protective effect of FME occurs via the suppression of these pathways.

The use of traditional plant medicines has been practiced for centuries, and despite a general insufficiency of supportive evidence concerning therapeutic efficacies, the use of herbal medicine continues to increase. The results of the present study confirmed previous observations that cytokine and MLDS activate the NF-κB pathway and induce β-cell dysfunction. In addition, the results of this study demonstrate that FME has a β-cell protective effect. Specifically, FME completely counteracted the development of type 1 diabetes in response to MLDS, and this was paralleled by a completely preserved β-cell mass. Since treatment with FME was not accompanied by serious side effects in mice, further clinical evaluation of FME is warranted to determine its value for the treatment of type 1 diabetes.

**Acknowledgements**

This work was supported by the Regional Research Centers Program of the Korean Ministry of Education and Human Resources Development through the Center for Healthcare Technology Development, and by a grant from the Ministry of Science and Technology (MoST)/Korea Science and Engineering Foundation (KOSEF) through the Vestibulo-cochlear Research Center (VCRC) at Wonkwang University (R13-2002-055-0000-0).

**References**


